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Background: One of the most important tasks of the SWEET study is
benchmarking the data collected. Information on the occurrence of the disease
of diabetes, the treatment, and their outcomes in children from the different
member states of European Union (EU) is crucial. How the collection of data
is realized is essential, concerning both the technical issues and the results. The
creation of SWEET Centers of Reference (CoR), all over Europe will be
facilitated by the access to safe data collection, where legal aspects and privacy
are ascertained.
Objective: To describe the rationale for- and the technical procedure in the
data collection implementation, in the SWEET study.
Subjects: Selected data on all patients treated at SWEET CoR are collected.
Methods: The SWEET project data collection and management system,
consists of modular components for data collection, online data interchange,
and a database for statistical analysis.
Conclusion: The SWEET study and the organization of CoR aims for the
goal of offering an updated, secure, and continuous evaluation of diabetes
treatment regimens for all children with diabetes in Europe. To support this
goal, an appropriate and secure data management system as described in this
paper has been created.
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Priority areas in public health programs within the
European Union (EU) are the development of health
information, recognition of strategies for the best
treatment of severe diseases, and information exchange
on these (1). Support is given to disease knowledge
projects relating to their occurrence, treatments, risk
factors, risk reduction strategies, cost of illness, and
social support, in terms of developing best practice
recommendations.
One of the most important tasks of the SWEET
project is benchmarking the essential collected data,
despite major differences in social and economic, as
well as cultural and educational levels across Europe,
within and between the countries (Eurostat).
It is essential to describe how the collection of data
on childhood diabetes is realized, concerning both
the technical issues and the results. Information on
the occurrence and the costs of the treatment for
children in different Member States of EU is crucial.
It is also important to elucidate the occurrence of
age appropriate education- and training programs for
healthcare professionals..
The creation of SWEET reference centers, centers of
reference (CoR), all over Europe will be facilitated by
the access to the data collected and processed, although
there is a need for local accommodation.
By prospective, at least annual evaluation and
open discussion of the individual centers owned
computerized data, both within the local team as well as
by comparing these data with other pediatric diabetes
centers in Europe, the hypothesis is that the level of
care and education will grow (2). As a consequence, the
outcome of the patients in terms of metabolic control
and the degree of acute and long-term complications,
should improve.
Appropriate, safe, and reliable data collection is the
essential basis for the evaluation and comparison of
data (3).
This paper will present the technical data collection
procedure of the benchmarking process, between
the current European Centers, the data safety
system, as well as the legal privacy aspects (4).
We will also propose ways to improve the local
outcome by using the registry and benchmarking
possibilities, with the hope and expectation that many
pediatric diabetes centers in Europe will accede, and
make use of the opportunity to participate in the
collaboration.
Methods
The SWEET project data collection and management
system consists of modular components for data
collection, online data interchange, and a database
for statistical analysis (Fig. 1).
Data collection and online data interchange
(i) [dpv2]1 diamax2 – a local diabetes management
system (electronic health record, EHR)
(ii) sweetconv3 – a conversion tool used for existing
databases with EHRs
[dpv2] diamax (Fig. 2) is not only a professional docu-
mentation software but also a helpful management
system for diabetes specialists, and was developed
in cooperation with the German Diabetes Associa-
tion (DDG) and International Society for Pediatric
and Adolescent Diabetes (ISPAD). [dpv2] diamax is a
module of the extensive healthcare platform dpv2. It
facilitates a corporate administration of patient data
for different disease patterns, e.g., ‘diabetes’, ‘cystic
fibrosis’ or ‘diabetes during gravidity’ (including both
gestational and pre-existing diabetes).
[dpv2] diamax, allows the documentation of all
the relevant information for the diabetes sector
respectively, and takes the data from the practice
administration system and provides it usefully for inter-
nal quality management or for external benchmarking.
In addition to detailed evaluation possibilities, the
system also offers a flexible statistic tool, cohort
comparison, graphical assessment possibilities, and is
able to generate all kind of release documents such as
doctor’s letters, therapy plans, patient summaries or
quick patient statuses. The dpv2 healthcare platform
is implemented as a client–server application, and is
therefore suitable for all kinds of networks. It allows
usage within a local network, e.g., within a prac-
tice/hospital, within the framework of an institutional
network through a wide area network (WAN) or via
the internet. It is possible to upload the data to the
SWEET central database, through a special interface.
In the cases, where pre-existing databases are in
place and [dpv2] diamax is not utilized, participating
centers can use the conversion tool sweetconv (Fig. 3)
to upload their data to the central database.
sweetconv therefore imports and utilizes data from
existing data sources which needs to be either of an
Excel, Access, or CSV4 format. sweetconv uses its
own structured query language (SQL)5-database to
store imported data. During the process of importing
the data into its own database, sweetconv is able to
do certain conversion tasks to make the data retrieved
from the data source file compatible with the needs
of the SWEET central database. These conversion
tasks can be configured, and the configuration can be
1Electronic health framework system for chronic diseases.
2Diabetes management module of DPV2.
3Used to convert data from different sources into a defined format
needed for the SWEET database.
4A file format used to store information in electronic files.
5A computer language used to query databases.
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Fig. 1. Dataflow.
stored in import profiles, so that it has to be done only
the first time it is used and can be reused for all the
subsequent imports.
After doing an import, the sweetconv user is able
to complete missing data or to add data which is not
contained in the source file but which is necessary for
participation in the SWEET project. Finally the data
can be uploaded to the SWEET central database.
Database and statistical analysis
(i) sweetonline – online data intermediary to collect
quality of life data
(ii) sweetbase6 – site-level and aggregate data analysis,
data archiving and retrieval.
Data privacy and security is an important issue (4).
sweetonline7 (Fig. 4) is built on the VisionTree
Optimal Care™ (vtoc) platform and meets the highest
research standards for human subject data, and is very
sensitive to participant confidentiality and consent.
Security is always a high priority not only to protect
6The system which stores the transmitted data.
7Patient portal for the patients of SWEET participants.
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Fig. 2. [DPV2] DIAMAX.
the data from hardware loss but also to ensure
confidentiality.
Each SWEET Center is able to enter and upload
data to the SWEET centralized database, via a secure
256-bit SSL8 encrypted internet connection using the
vtoc platform. vtoc servers employ power-on and
8Protocol used for secure data interchange on the Internet.
user passwords, virus protection, and battery backup
systems in a statement on auditing standards-70
(SAS-70)9 compliant data center with restricted access
to authorized maintenance through 24/7 biometric
security measures. Servers are constantly monitored
9A security audit standard used, for example, data centre
certification.
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Fig. 2. Continued.
for break-in attempts or other illegal activity. Personal
data storage is maintained with scrambled unique hash.
The vtoc is compliant with the EU privacy directive
and all of its tenets, as outlined below:
(i) Tenet 1-Notice: An individual has the right to
know that the collection of personal data will
exist. The personal data must be collected for
specified, explicit, and legitimate purposes, and
not further processed in a way incompatible with
those purposes.
(ii) Tenet 2-Choice: An individual has the right to
choose not to have the personal data collected.
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Fig. 3. SWEETCONV.
(iii) Tenet 3-Use: An individual has the right to know
how personal data will be used and to restrict its
use. Personal data may only be used for ‘legitimate
processing’ as described by directive details.
(iv) Tenet 4-Security: An individual has the right
to know the extent to which the personal data
will be protected. Organizations must implement
appropriate technical and organizational measures
to protect personal data. The measures must
be appropriate to the risks represented by the
processing and the nature of the data be protected.
(v) Tenet 5-Correction: An individual has the right to
challenge the accuracy of the data and to provide
corrected information. Personal data collected and
maintained by organizations should be up to date
and reasonable steps must be taken to ensure that
inaccurate or incomplete data is corrected.
(vi) Tenet 6-Enforcement: An individual has the right
to see legal relief through appropriate channels to
protect privacy rights.
To meet and maintain all six tenets of the EU privacy
directive, as described above, vtoc is implementing
and maintaining the Truste® third party security
certificate, as well as meeting Title 21 code of federal
regulations (CFR)10 Part 11 compliance standards,
10Code of Federal Regulations with European Annex compliance
criteria (Part 11) for electronic health data and electronic signatures
for de-identified research data management, which
includes compliance with the European Annex. The
sweetonline system maintains a user audit log,
encrypted password management and provide a de-
identified data import using secure hash algorithms
and encryption.
SWEETBASE
SWEET centers can analyze their own data and
access SWEET comparative benchmarking data from
participating sites. The benchmarking report is based
on the center profile. Therefore, the usefulness of the
report for the local CoR depends on how well the data
was collected and reported.
Synthesis
A patient’s record must be first created, in an electronic
format. This may be performed with the [dpv2] diamax
system, as described above, any electronic health record
(EHR) system or electronic data format such as Excel,
Access, or CSV file. A common data set and taxonomy
based on the basic information sheet (BIS) for children
and adolescents, the World Health Organization
to be considered trustworthy, reliable, and equivalent to paper
records.
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Fig. 4. SWEETONLINE patient portal.
Implementation of the St. Vincent Declaration, for
pediatric and adolescent diabetes data elements is
collected, and stored at the local center level. Data
from the BIS may be exported to sweetonline using
either the [dpv2] diamax system or the sweetconv data
conversion tool. sweetconv, maps core data elements
from disparate electronic data formats to sweetonline
for secure, de-identified data transport, and reporting.
Patient level data is de-identified on the local
level in the [dpv2] diamax system or sweetconv
tool, and sent to sweetonline via extensible markup
language (XML) file using secure transmission
channels. sweetonline receives the data through a
secure data transport layer, using hypertext transfer
protocol secured (HTTPS) encryption.11 Furthermore,
the sweetonline system encrypts user passwords and
maintains an audit log of all transactions including user
login date, time, page viewed, and action taken. During
the import process to sweetonline a de-identified
patient record is created with an instance of the BIS.
11Protocol used for secure data interchange on the Internet.
At this time, patient credentials to login to a secure,
online patient portal are also created.
With consent management on the local level
and by returning the created user credentials from
sweetonline to the transmitting system ([dpv2]
diamax or sweetconv), a patient will receive login
details to sweetonline to access its patient portal
from any internet location, including its own computer
environment or, e.g., a workstation at the clinic. In
its patient portal, for example, the patient is able to
complete the WHO-5 outcomes assessment, as well as
other quality of life instruments, which may be added
to the sweetonline system.
Using a time point management system within
sweetonline and the vtoc platform, the WHO-5 could
be delivered in intervals of 3 months for an active
duration for completion within 6 wk. These time points
and duration interval are managed by the SWEET
research registry via a user interface in sweetonline.
The collection of the anonymized BIS clinical
outcomes data and WHO-5 patient reported outcomes
data is done via the sweetbase database for patient-
level longitudinal data collection, statistical analysis,
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and quality data benchmarking. sweetbase provides
SWEET registry centers the ability to compare their
quality data using the BIS and WHO-5 data sets to
all participating CoR with user-friendly aggregate and
comparative reporting tools.
Subjects
A significant principle is that all patients at the CoR
where the patient and parents have consented to the
participation of the child in the registry should be
included. A selection bias by the clinic because of poor
metabolic control, poor compliance with the guidelines
in administrating the yearly quality follow-up, etc.
would compromise the validity of the data, and rule
out fair benchmarking between the centers.
Measurements
The submitted data are categorized as outcome and
process data (1). To evaluate the progress of the
clinic it is an important quality parameter not only to
report the values per se of the different variables but
also the degree of compliance to the guidelines, e.g.,
if the planned screening procedures are performed
according to the schedule. The registry can offer
an individualized and updated information on the
time of next screening for retinopathy, urine check
for microalbuminuria, etc. This reminder to the
diabetologist/diabetes nurse, facilitates compliance
with the guidelines and guarantees the right of the
patient to receive evidence-based high level of care.
Protocol
The collection of data must be in agreement with the
protocol based on International Society for Pediatric
and Adolescent Diabetes (ISPAD) guidelines, in order
to obtain the most secure and valid data. For example,
the height and weight of the child should be recorded
without the shoes and in light underclothes (5). The
blood pressure should be measured on the left arm
with an age- and size appropriate cuff with the
patient in an upright position (6). The hemoglobin
A1c (HbA1c) method should be continuously validated
at a centralized quality laboratory to make sure that
an eventual drift in the method is recognized and
adjusted (7). A future prospect may be that the CoR
could affiliate with the same laboratory for some of the
laboratory parameters, e.g., HbA1c (8).
Data analysis
HbA1c is reported once every 3 months as well as
height, weight, and blood pressure of patients above
the age of 10. BMI is auto-calculated from raw data.
During 2011/2012, the following data will be collected:
MA (microalbuminuria) – once a year, specified in
units (mg/l; μg/min; MA/creatine in ratio), lipids,
eye examination, screening for thyroid- and celiac
disorders. Personal data like, the date of diagnosis,
degree of metabolic disturbance at diagnosis [Diabetic
ketoacidosis (DKA) or not], date of diagnosis of
associated illnesses such as thyroid- and celiac disease
as well as ethnicity are recorded. The treatment
modality is essential to prospectively evaluate the effect
of insulin pumps, sensors, and other future technical
equipment, and correlate the costs with the metabolic
outcome.
The data is to be submitted on a regular basis,
for example, quarterly within 1 month from the end
of each quarterly period. An auto-reminder by email
will be sent to CoR-users of the system. The system
automatically calls attention to generated data, which
is outside of the expected range. Although a complete
upload of data according to the protocol is desirable,
some data, for example, information on demographic
parameters are mandatory.
Results
It is not the subject of this paper to report on the
results of specific data. However, the centers from
different countries in Europe reporting their 2011
data have had a high fill in rate of almost 100%. The
number of patients treated varied significantly between
the centers. The mean age of the patients is dependent
on whether the pediatric diabetes clinic is also caring
for young adults. This allows one to determine the age
of a patient at the time of his or her transition to adult
care. We can conclude that in centers with about the
same tradition of transferring the patients at the age
of 18 yr, the mean age of the whole group is about
the same in the different countries, around 13 yr. It
has been a trend during the latest 20 yr in Northern
Europe to lower age of diagnosis (9) but the bulk of
patients are teenagers. The diabetes duration of the
treated patients goes in parallel as expected with the
age of the patients and is around 7 yr.
Discussion
Through this health information technology infras-
tructure, it is indispensable to be able to aggregate
diabetes relevant information and deliver more efficient
and quality care by networking all parties of a patient’s
care team. The outcome of the interdisciplinary care in
medical practices, hospitals, and ambulatory health-
care centers, as well as the implementation of integrated
utility supply contracts needs evaluation. A reliable,
computerized, on-line registry for diabetes-related
variables facilitates and permits, sharper focus on
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indicators of quality and the processes in the workplace
as well as the local out-patient clinic. The registry can
not only be used for the comparison of data within
the diabetes unit but also as a tool for comparison
and benchmarking between different units within and
between countries.
In Sweden, there has been a running national
registry of pediatric diabetes data (SWEDIABKIDS)
since 2000 and since the web-based, on-line registry
was introduced in January 2008, providing clear results
from every clinic, a trend toward better outcome data
may be expected in those clinics actively using the
data (10).
Based on the data delivered, direct feed-back
information is available, at both the individual patient
level, as well as on a group level. The registry can give
support for decisions according to the guidelines, such
as screening time for microalbuminuria, retinopathy,
and celiac- or thyroid disease. In pediatrics, the age
of the patient is an important factor for appropriate
evaluation of laboratory values as well as for other
indicators of health. The computerized system allows
age-appropriate norms to be integrated, facilitating,
for example, the estimate of whether or not the blood
pressure level measured is within the normal range.
Diabetes is a chronic disease where a high quality
of care has a proven effect on the prognosis of the
individual patient in terms of life expectancy and
quality of life (11). It also has an obvious effect on
society in terms of medical costs, insurance expen-
ditures, and working capacity of the effected patient
(12). A high quality of care is possible by prospective
measurement of the target achievement by the single
diabetes unit. The guidelines to follow should be
based on the evidence, relying on solid data from a
high number of patients, who are treated according
to a well-defined policy and updated according to the
results. The possibility in sweetonline for the patient
to login for access to his/her own patient portal and to
fill in forms on quality-of-life measurement is a major
step forward toward person-centered care (13).
Implementation research is important to consider,
when the aim is to realize evidence-based medicine.
The theoretical framework of implementation is based
on a strategic change (Pettigrow and Whipp: Strategic
Management of Change):
Why-with relevance to context
What-in terms of context
How-in relation to process
Successful strategic changes are based on key people
leading the change, quality and coherence of policy,
supportive organizational culture, good managerial
and clinical relations, co-operative interorganizational
networks, and simplicity of organizational goals and
priorities.
The SWEET study and the organization of CoR aims
to incorporate all of these demands for successful
change.
To support this goal, an appropriate and secure data
management system as described has been created.
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